A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer.

Trial Profile

A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Conatumumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 01 Oct 2013 Final analysis published in Cancer.
    • 12 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Aug 2009 Actual patient number (202) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top